Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL17352177 | 1.00 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL587923 | 0.98 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL587922 | 0.98 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL17352178 | 0.96 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL31241164 | 0.96 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL10620093 | 0.96 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL12470732 | 0.94 | GSR (0.57) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL25283016 | 0.93 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL896279 | 0.93 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Lysine SCHEMBL5691753 | 0.93 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157936-B1 | MINERAL AMINO-ACID COMPLEXES OF ACTIVE AGENTS | THETIS PHARMACEUTICALS LLC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9999626-B2 | Mineral amino-acid complexes of active agents | THETIS PHARMACEUTICALS LLC (US) | 2018-06-19 | — | — | US | disclosed |
| US-20160199385-A1 | Mineral Amino-Acid Complexes of Active Agents | CONNECTICUT INNOVATIONS, INC., AS COLLATERAL AGENT | 2016-07-14 | — | — | US | disclosed |
| US-9242008-B2 | Mineral amino-acid complexes of fatty acids | THETIS PHARMACEUTICALS LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150366980-A1 | Mineral Amino-Acid Complexes of Fatty Acids | CONNECTICUT INNOVATIONS, INC., AS COLLATERAL AGENT | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366980-A1 | Mineral Amino-Acid Complexes of Fatty Acids | FABP4, FABP3, SLC27A2 | GSR 2273/4885GNAI3 2204/4885GNAO1 3939/4885 |
| US-20160199385-A1 | Mineral Amino-Acid Complexes of Active Agents | S100A6, S100A4, SLC7A1 | GSR 4169/4885GNAI3 1971/4885GNAO1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.